AllDocs -> cancers

A210 : Thyroid cancer tissues For research use only (formalin fixed) Specifications: • No. of cases: 33 • Tissue type: Thyroid cancer tissues • No. of spots: 2 spots from each cancer case (66 spots) 4 non-neoplastic spots (4 spots) • Total spots: 70 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A210 : Thyroid cancer tissues For research use only (formalin fixed) Summary of tissue spots No. Sex Age Key Word Surgery TNM Stage 1 1, 2 f 49 thyroid gland: papillary carcinoma dissection T3N1aM0 2 3, 4 f 48 thyroid gland: ...

ThyCa: Thyroid Cancer Survivors’ Association, Inc. SM thyca@thyca.org www.thyca.org Reference Book for Patients and Caregivers Thyroid Cancer : A Guide for Patients Douglas Van Nostrand, M.D., Gary Bloom, and Leonard Wartofsky, M.D., Editors. 28 contributing authors. 336 pages. Over 60 photos, tables, and checklists. Keystone Press, 2004. This in-depth reference has 28 contributing authors, including 18 physicians from the many specialties involved in thyroid cancer care and research, from several major medical centers in the US and Canada. Chapter authors also include mental health professionals, other specialists, thyroid cancer patients, and a caregiver. The foreword is by Ernest L. Mazzaferri, M.D., Endocrinologist and President-Elect, American Thyroid Association. All proceeds above the cost, from books ordered from ThyCa, will help support ThyCa’s free ...

Anesthetic Management of Metastatic Thyroid Cancer with Perioperative Hypoxemia Nazia Choudhury, MD, Mary M. Joseph, MD, Vikash Modi, MD, Dennis Maceri, MD Department of Anesthesiology, Keck School of Medicine, Los Angeles County+University of Southern California Medical Center, Los Angeles, CA Distant metastases of differentiated thyroid cancer are usually localized in the lungs or bones. The incidence of distant metastases in patients with Papillary Thyroid cancer is approximately 2-3% (1) and involvement of the central nervous system is rare. Case Report: A 34-year-old male, height 5’6”, weight 107kg, ASA 1V with Papillary Thyroid Cancer and metastases to the Lungs and the Brain was scheduled for a right occipital craniotomy with excision of intracranial mass and total thyroidectomy. The patient had no previous medical history and presented to the hospital with a history of recent onset diplopia ...

1 Minutes – Annual General Meeting May 14, 2005 Canadian Thyroid Cancer Support Group (Thry’vors) Inc. Meeting – May 14, 2005, 9:30 a.m. Ottawa Hospital,1967 Riverside Drive, Ottawa Attendees: Rita Banach, President, Toronto Melissa Pecile, Member, Toronto Louise Beggs, Director, Chesterville Nola Goertz, Member, Edmonton Tara Gallagher, Member, Toronto Patrick Belford, Member, Toronto Dianne Dodd, Director, Ottawa Lorilea Erratt, Director, Chesterville Grace Wright, Secretary-Treasurer, Toronto Ann Dreger, Director, Aurora Louise Rouiller, Supporter, La Prairie, QC Sylvain Pratte, Member, La Prairie, QC Shali Manuel, Member, Halifax Megs Watt, Member, Halifax Meeting was chaired by Rita Banach. 1. Call to order Rita welcomed the attendees and affirmed that quorum had been established. Proxies were held by Rita for Beth Rajnovich (Vice-President), ...

THYROID CANCER MEDICAL APPENDIX DEFINITION 1 Thyroid nodules are common with a spectrum ranging from benign to malignant. Some nodules are true benign adenomas and others are definite carcinomas but between these many nodules are potentially malignant and the precise relationship between benign and malignant nodules is speculative. Although relatively rare, accounting for less than 1% of new malignancies annually in Britain, thyroid cancer is the most common type of endocrine malignancy. Cancers of the thyroid are usually classified into the following histological groups: • Papillary carcinoma • Follicular carcinoma • Medullary carcinoma • Anaplastic carcinoma 2 Malignancies of other tissues may also occur in the thyroid gland: 2.1. Miscellaneous tumours . The thyroid may be the site of non-Hodgkin’s lymphoma, which accounts for up to 50% of ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN THYROID CANCER TISSUE MICROARRAY Catalog Number: TMA-011 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched thyroid tissue is provided for comparison to the cancer tissue. Cases : 68 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Thyroglobulin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

FOR IMMEDIATE RELEASE UNIQUE NEW COOKBOOK WILL CHANGE THE LIVES OF THYROID CANCER PATIENTS THE LOW IODINE COOKBOOK: EASY AND DELICIOUS RECIPES & TIPS FOR THYROID CANCER PATIENTS , by Norene Gilletz, ISBN 1-4210-6691-3 The Low Iodine Diet Cookbook is the ultimate cookbook for thyroid cancer patients who need to be on the low iodine diet (LID) for radioactive iodine treatment or scans. The book is written by Norene Gilletz, a renowned cookbook author who is experienced with special diets and substitutions—particularly diets that do not allow dairy, or store-bought breads. This unique cookbook contains more than 250 kitchen-tested recipes, over 20 milk substitutes and variations, and an exhaustive nutritional analysis chart. At last, LID recipes that are easy and delicious—by the woman critics hail as the “Julia Child” of specialty diet cooking. Always keeping her motto that “food that is ...

Locally advanced thyroid cancer Kepal N. Patel and Ashok R. Shaha Purpose of review The purpose of this review is to summarize existing literature with respect to locally advanced thyroid cancer and define the intricacies of preoperative evaluation, surgical management of involved sites and postoperative treatment. Recent findings Locally invasive thyroid cancer is an uncommon disease process, which carries significant morbidity and mortality. Current treatment modalities include appropriate surgery, radioactive iodine treatment and external beam radiation therapy. Proper evaluation of the extent of disease, with complete gross tumor removal, is paramount in managing this difficult problem. Surgical treatment is still the mainstay for locally advanced thyroid cancer . Summary Little progress has been made in advancing the treatment of locally advanced thyroid ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Thyroid Cancer and other Thyroid Diseases and Exposure to Ionizing Radiation 1 Thyroid Cancer and other Thyroid Diseases and Exposure to Ionizing Radiation Summary: Strong evidence has been recorded of a possible connection between thyroid cancer and exposure to ionizing radiation. This evidence is based upon studies conducted at Los Alamos National Laboratory, studies of nuclear workers at other sites, and others exposed to ionizing radiation. These findings are consistent with the National Research Council’s determination that the thyroid is sensitive to ionizing radiation. Thyroid cancer is designated as a “specified” cancer under the Energy Employees Occupational Illness Compensation Program Act. Historically, thyroid cancer incidence for ...

CANCER Thyroid cancer incidence trends in Belarus: examining the impact of Chernobyl Martin C Mahoney, 1 Silvana Lawvere, 1 Karen L Falkner, 1 Yuri I Averkin, 2 Vladislav A Ostapenko, 1 Arthur M Michalek, 3 Kirsten B Moysich 1 and Philip L McCarthy 4 Accepted 18 March 2004 Background While prior studies of thyroid cancer incidence within Belarus have increased since the 1986 Chernobyl reactor accident, the magnitude of increase is not well quantified. Methods Using Belarussian national cancer registry data, trends in average annual age- adjusted thyroid cancer incidence rates were examined by calendar year and gender. Incidence rates were also examined across specified time intervals, for specific age groups at diagnosis, and in ‘higher exposure’ ...

Table 2: Current clinical trials on redifferentiation therapy for thyroid cancer [98] Study Condition Treatment/intervention Collaborators Status Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer University of California, San Francisco Drug: rosiglitazone Procedure: biological response modifier therapy, differentiation therapy, radiosensitization recurrent thyroid cancer stage IV follicular thyroid cancer insular thyroid cancer stage IV papillary thyroid cancer recruiting, pilot study National Cancer Institute (NCI) FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer refractory thyroid cancer or other advanced cancer Patients will receive a 4-hour infusion ...

Table 1: Retinoic acid redifferentiation therapy of thyroid cancer : published clinical trials RAIU Tg levels PET tumor burden comments ref. patients treatment 1) (13- cis RA dose) ? 2) ? ? ? ? ? ? ? ? ? ? 50 1.5 mg/d/kg; 5 w 21/50 29/50 30/50 8/50 12/50 n.d. 3) n.d. n.d. 6/37 22/37 9/37 Responder (RAIU ? and/or Tg levels ? or tumor size ?): 10 patients; follow-up: 6 – 30 m 35 12 1.0-1.5 mg/d/; =5 w 5/12 7/12 n.s. 4) n.s. n.s. 2/5 1/5 2/5 n.d. n.d. n.d. Responder (RAIU ?): 3 patients faint, 2 patients therapeutically significant 39 1.0 mg/d/kg; 8 w; 6/18 n.s. n.s. n.s. ...

INTRODUCTION Whole body iodine-131 (I-131) scan remains the mainstay for the detection of recurrent or metastatic lesions of patients with well-differentiated thyroid cancer . The presence of uptake outside the areas of physiologic elimination such as salivary glands, nasopharynx, urinary bladder, and stomach is sugges- tive of metastasis. However, many false-positive findings on I-131 diagnostic and therapeutic scans have been reported (1-8). It is very important to recognize false positive findings to avoid unnecessary ablation treatment. Previously, gallbladder localization of I-131 during post- therapy scan of well-differentiated thyroid cancer has been described (9, 10). However, no other study has reported nor- mal gallbladder accumulation of I-131. We report a case of marked I-131 accumulation in normal gallbladder and this is the first report of normal gallbladder visualization in ...

ABSTRACT Background: The diagnosis of thyroid carcinoma during the course of lobectomy for a dominant nodule occasionally cannot be rendered on the basis of frozen section. Once the diagnosis of carcinoma is made, the question of completion thyroidectomy arises. Patients and Methods: During a period of 3 years, 28 patients diagnosed with well-differentiated thyroid cancer (WDTC), and operated upon with less than total thyroidectomy, were admitted to our department. Patients had no clinical or radiological evidence of any residual disease at the time of admission. All were submitted for total thyroidectomy. Results: There were 7 men and 21 women (1:3), and the average age was 38.6+/-1.3 years (range, 20 to 62 years). The postoperative morbidity in completion thyroidectomy consisted of transient hypoparathyroidism in 2 patients (7.1%), permanent hypoparathyroidism in 1 ...

In Pennsylvania, the average annual (1998-2002) age-adjusted incidence rate for thyroid cancer among females was nearly three times the rate for males (14.9 per 100,000 versus 5.0, respectively). The average annual rate for white females (15.1 per 100,000) was nearly 25 percent higher than the rate for black females (12.1). Thyroid cancer is one of the rarer types. However, the annual age-adjusted incidence rates have been rising dramatically among both males and females. In 2002, the 1,591 cases of invasive thyroid cancer was the highest number ever reported to the Pennsylvania Cancer Registry. The 2002 age-adjusted incidence rate (12.3 per 100,000) was over twice as high as the 1993 rate (5.3). Higher incidence rates among females suggest the role of hormonal factors in the etiology. Almost 29 percent of the invasive thyroid cancer cases diagnosed between 1998 and 2002 occurred among residents under 40 years of age. Approximately ...

284 FDG-PET in Head and Neck, and Thyroid Cancer Homer A. Macapinlac, MD FDG-PET has become a standard clinical imaging modality in patients with head and neck cancer . It contributes valuable information in localizing a primary tumor in patients with neck nodal metastases from an unknown primary, in the staging of primary head and neck cancer , and in the detection of recurrent disease. In addition, FDG-PET provides inde- pendent prognostic information in patients with newly diagnosed and recurrent head and neck cancer . PET-CT improves lesion localization and accuracy of FDG-PET and is strongly recommended in patients with head and neck cancer . After thyroidectomy, FDG-PET has proven useful in patients with clinical or serological evidence of recurrent or metastatic thy- roid carcinoma but negative whole body iodine scan. PET shows metastatic disease in up to 90% of these patients, thereby ...

P.O. Box 372 372, 1211 Geneva 19, Switzerland Telephone +41 22 730 42 22 - Telefax +41 22 733 03 95 - E-mail: secretariat@ifrc.org - Web site: wwww.ifrc.org 34/05 Geneva, 26 April 2005 Declining donor support may jeopardize Red Cross Red Crescent Chernobyl thyroid cancer detection programme On the 19th anniversary of the world's worst nuclear accident and with Chernobyl-related cancer rates predicted to peak from 2006 to 2020, the International Federation of Red Cross and Red Crescent Societies is warning that Chernobyl must not become a forgotten disaster. The Federation expressed its extreme concern that funding trends for 2006 and beyond will not allow it to continue life-saving screening for thyroid cancer in affected areas of Belarus, Ukraine and Russia and that it was essential the programme be sustained for the next 15 years. "Our funding will reach critically low levels at the end of 2005, ...

1 Now available Thry’vors Library of Visual Presentations, Lectures and TV Appearances Disk 001 “ Thyroid Cancer – Diagnosis, Treatment and Aftercare” a Forum presented by the Burlington Hamilton Area Chapter of the Thyroid Foundation of Canada and Dell Pharmacy This 2 hour panel forum held in the Hamilton Spectator auditorium on September 24, 2003, includes presentations from the following individuals: 1. William Harper, MD, FRCP (C) Endocrinologist, Hamilton Health Sciences 2. Karen Gulenchyn, MD, FRCP (C) Chief, Nuclear Medicine, Hamilton Health Sciences 3. Stuart Archibald, FRCP (C) Head and Neck Surgical Oncologist, St. Josephs Healthcare Hamilton 4. Tom Smiley, B.Sc.Phm., Pharm.D. Dell Pharmacy, Brantford, Ontario 5. Rita Banach, B. Sc., DCS, President, Canadian Thyroid Cancer Support Group (Thry’vors) Inc. Dr. Harper’s gave an overview of ...

Follow-up Testing for Thyroid Cancer Patients To assess whether all thyroid cells have been destroyed, two principal diagnostic tests are used, a whole body scan, and a thyroglobulin blood test. These tests need to be done periodically, and it is necessary to have the levels of TSH ( thyroid stimulating hormone) elevated during the test, which can be achieved either by withdrawing a patient from thyroid hormone, or with the use of recombinant TSH. On the day that the scan is done, a blood test for TSH and the thyroglobulin protein should also be obtained. As it can take a few days for the test results to become available, patients who have been withdrawn from thyroid hormone may go back on T3 (Cytomel) while waiting for the all results to come back whereas patients who received recombinant TSH simply continue on their thyroxine. Withdrawal Protocol Discontinue thyroxine at least 6 weeks ...

NYCRIS Regional Audit The Management of Thyroid Cancer Steering Group Meeting Blackwell Grange Hotel, Darlington, 3:00 p.m., 18 th July 2001 Present: Dr S Atkin, Consultant Endocrinologist, Hull Royal Infirmary Dr C Bennett, Projects Manager, Information Services, NYCRIS Dr C Coyle, Consultant Clinical Oncologist, Cookridge Hospital Mr J England, Consultant ENT Surgeon, Hull Royal Infirmary Dr J Hardman, Consultant Clinical Oncologist, South Cleveland Hospital Mrs C Ingham, The British Thyroid Foundation Mr M Lansdown, Consultant Surgeon, St James’s University Hospital Dr U Mallick (Chairperson), Consultant Clinical Oncologist, Northern Centre for Cancer Treatment Mrs R Tate, Projects Co-ordinator, Information Services, NYCRIS Apologies: Miss P Durning, Consultant Surgeon, South Cleveland Hospital Dr S Gilby, Consultant Endocrinologist, ...

Stanford University, March 8, 2005 Current Trends in Thyroid Cancer Quan-Yang Duh Professor of Surgery University of California San Francisco Page 2 Epidemiology - Thyroid Cancer 2004 SEER 24, 200 new cases of thyroid cancer in 2004 1,500 died of thyroid cancer in 2004 290,000 survivors of thyroid cancer in USA The incidence doubled from 1990 4% increase per year Page 3 Thyroid Cancer : Incidence and Mortality Page 4 Current Trends in Thyroid Cancer Total thyroidectomy: rationale, technique Routine preoperative ultrasonography – Limited but targeted lymphadenectomy Familial cancers – Prophylactic thyroidectomy PET scan Page 5 Recommended Treatment ...

!"# !$%&'%(!)* #+%,!-./)01%2!34).3#+%5$6.1/ '%7! 6.3!1 Waikato District Health Board Thyroid cancer Mortality (0-74) Introduction Rationale Methodology Data Coverage Period Method Description Interpretation International Classification of Disease Codes (ICD Version 9 & 10) ICD 9 ICD 10 Findings 1 Ethnicity Volume Trend 2 Age Gender Volume Proportion Profile 3 Age Ethnicity Volume Profile - All years 4 Age Ethnicity Volume Proportion Profile (All Years) 5 Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 6 Maori Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 7 Paciifc People Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 8 Other Ethnicity Age Standardised Trend - Waikato District Health Board ...

!"# !$%&'%(!)* #+%,!-./)01%2!34).3#+%5$6.1/ '%7! 6.3!1 Waikato District Health Board Thyroid cancer Mortality Introduction Rationale Methodology Data Coverage Period Method Description Interpretation International Classification of Disease Codes (ICD Version 9 & 10) ICD 9 ICD 10 Findings 1 Ethnicity Volume Trend 2 Age Gender Volume Proportion Profile 3 Age Ethnicity Volume Profile - All years 4 Age Ethnicity Volume Proportion Profile (All Years) 5 Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 6 Maori Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 7 Paciifc People Age Standardised Trend - Waikato District Health Board versus NZ rate per 10,000 persons 8 Other Ethnicity Age Standardised Trend - Waikato District Health Board versus ...

tic) Gaucher’s disease that is a rare form, of which only a few cases have been reported. Morrison et al . 2 described 2 patients with asplenomegalic Gaucher’s disease in whom the presenting symptoms were pur- pura and anaemia respectively and the diagnosis was established only after bone marrow examination. The authors cited two more cases of Gaucher’s disease without splenomegaly. In a series of 34 patients, Matoth et al . 3 treated only one 9-year-old patient in whom the spleen was not palpable. In our series of more than 30 cases with Gaucher’s disease, we had one asplenomegalic patient. Since there is a correla- tion between the size of the spleen and the severity of the symptoms including the hematological findings, it is possible that some asymptomatic patients with Gaucher’s disease remain undiagnosed. With the introduction of enzyme replacement therapy, ...

Thyroid cancer incidence trends in Belarus: examining the impact of Chernobyl Martin C Mahoney, 1 Silvana Lawvere, 1 Karen L Falkner, 1 Yuri I Averkin, 2 Vladislav A Ostapenko, 1 Arthur M Michalek, 3 Kirsten B Moysich 1 and Philip L McCarthy 4 Accepted 18 March 2004 Background While prior studies of thyroid cancer incidence within Belarus have increased since the 1986 Chernobyl reactor accident, the magnitude of increase is not well quantified. Methods Using Belarussian national cancer registry data, trends in average annual age- adjusted thyroid cancer incidence rates were examined by calendar year and gender. Incidence rates were also examined across specified time intervals, for specific age groups at diagnosis, and in ‘higher exposure’ regions compared ...

"Radiation & Risk", 1996, issue 8 Scientific Articles 15 Leukemia and thyroid cancer in emergency workers of the Chernobyl accident: estimation of radiation risks (1986-1995) Ivanov V.K., Tsyb A.F., Gorsky A.I., Maksyutov M.A., Rastopchin Eu.M., Konogorov A.P., Korelo A.M., Biryukov A.P., Matyash V.A. Medical Radiological Research Centre of RAMS, Obninsk The work makes a direct epidemiological assessment of radiation risks in induction of leukemia and thyroid cancer in emergency workers after the Chernobyl accident. The Russian National Medical Dosimetric Registry has a compilation of data for 168 thousand emergency workers as of 01.01.1996. Analysis was per- formed of 48 leukemias and 47 thyroid cancers diagnosed and verified in emergency workers. The estimated radiation risks are: for leukemia - excess relative risk per Gy (ERR/Gy) is 4.30 (95% ...

1 Proposals of guidelines (june 2004) Follow up of well-differentiated thyroid cancer (DTC) BSNM, WG Endocrinology and WG Metabolic Therapy G. Andry (I. Bordet, Bruxelles), P. Bergmann (CHU Brugmann, Bruxelles), P. Bourgeois (I. Bordet, Bruxelles), B. Corvilain (Erasme, Bruxelles), C. Daumerie (CU St Luc, Bruxelles), J. Foidart – Willems (CHU, Liège), P. Flamen (I. Bordet, Bruxelles), J.Hermans (C H de Jolimont), F. Jamar (CU St Luc, Bruxelles), D. Glinoer (CHU St Pierre, Bruxelles), E. Laurent (Edith Cavell, Bruxelles), R. Moreno Reyes (Erasme, Bruxelles), E. Harmoir (CHU, Liège), P. Paulus (CHR Citadelle, Liège), L. Plat (I. Bordet, Bruxelles), J.P. Squifflet (CU St Luc, Bruxelles), A. Van Coevorden (CHU Tivoli, La Louvière), P. Van Crombrugge (OLV, Aalst) Introduction The yearly incidence of thyroid carcinoma in Belgium is estimated at 2 to 4 cases/ 100.000, most of them being well-differentiated. ...

1 TRENDS IN THYROID CANCER IN SWITZERLAND: COULD A CHERNOBYL EFFECT BE DISCLOSED? Fabio Montanaro 1 , Pierre Pury 2 , Andrea Bordoni 1 , Jean-Michel Lutz 2,3 and the Swiss network of cancer registries (ASRT) 1 Ticino Cancer Registry, Locarno 2 Association of Swiss Cancer Registries, Geneva 3 Geneva Cancer Registry, Geneva Carcinoma of the thyroid gland is an uncommon malignancy, accounting for approximately 1% of total cancer cases in developed countries (WCR 2003). In areas not associated with nuclear fallout (how do you define this, or do list them), the annual incidence of thyroid cancer ranges between 2.0-3.8 cases per 100,000 in women and 1.2- 2.6 per 100,000 in men, women of childbearing age being at highest risk. Low figures are ...

All requested information must be provided to process registration. American Thyroid Association Frontiers in Thyroid Cancer : Clinical Care and REGISTRATION FORM Research for the Future Deadline for receipt of advance registration is April 7, 2005. Baltimore Marriott Waterfront Baltimore, Maryland April 14-17, 2005 All Fees are in US Dollars. __ First name __ Last name __ Nickname for badge Professional degree(s) (please list one): _ a. MD b. PhD c. MD, PhD d. RN e. Other __ Organization __ Address 1 __ Address 2 _ __ City State Zip code + 4 If outside the U.S., country/city code : __ Country (_)_ (_) Phone Fax __ E-mail address 1. I ...

ThyCa: Thyroid Cancer Survivors’ Association, Inc . SM An all-volunteer non-profit 501 (c)(3) organization of thyroid cancer survivors, family members, and health professionals P.O. Box 1545, New York, NY 10159-1545 Toll Free 1-877-588-7904 gbloom@thyca.org www.thyca.org Medical Advisory Council Kenneth B. Ain, M.D. University of Kentucky Medical Center Lexington, KY Kenneth D. Burman, M.D. Washington Hospital Center Washington, DC Jeffrey A. Cooper, M.D. University of Pittsburgh Medical Center Pittsburgh, PA Robert F. Gagel, M.D. University of Texas, M.D. Anderson Cancer Center Houston, TX Bryan R. Haugen, M.D. University of Colorado Health Sciences Center Denver, CO Paul W. Ladenson, M.D. The Johns Hopkins Medical Institutions Baltimore, MD Donald Margouleff, M.D. North Shore University ...